key: cord-0290650-uyn8dnmv authors: Kalman, J. L.; Burkhardt, G.; Adorjan, K.; Barton, B. B.; De Jonge, S.; Eser-Valeri, D.; Falter-Wagner, C. M.; Heilbronner, U.; Jobst, A.; Keeser, D.; Koenig, C.; Koller, G.; Koutsouleris, N.; Kurz, C.; Landgraf, D.; Merz, K.; Musil, R.; Nelson, A. M.; Padberg, F.; Papiol, S.; Pogarell, O.; Perneczky, R.; Raabe, F.; Reinhard, M. A.; Richter, A.; Ruther, T.; Simon, M. S.; Schmitt, A.; Slapakova, L.; Scheel, N.; Schule, C.; Wagner, E.; Wichert, S. P.; Zill, P.; Falkai, P.; Schulze, T. G.; Schulte, E. C. title: A blueprint for biobanking in everyday clinical practice in psychiatry: The Munich Mental Health Biobank date: 2022-05-07 journal: nan DOI: 10.1101/2022.05.05.22274583 sha: dbe50c9ae9fb47a5193712ab291743d0b3920605 doc_id: 290650 cord_uid: uyn8dnmv Translational research on complex, multifactorial mental health disorders, such as bipolar disorder, major depressive disorder, schizophrenia, and substance use disorders requires databases with large-scale, harmonized, and integrated real-world and research data. The Munich Mental Health Biobank (MMHB) is a mental health-specific biobank that was established in 2019 to collect, store, connect, and supply such high-quality phenotypic data and biospecimens from patients and study participants, including healthy controls, recruited at the Department of Psychiatry and Psychotherapy and the Institute of Psychiatric Phenomics and Genomics, University Hospital of the Ludwig-Maximilians-University (LMU), Munich, Germany. Participants are asked to complete a questionnaire that assesses sociodemographic and cross-diagnostic clinical information, provide blood samples, and grant access to their existing medical records. The generated data and biosamples are available to both academic and industry researchers. In the current manuscript, we outline the workflow and infrastructure of the MMHB, describe the clinical characteristics and representativeness of the sample collected so far, and reveal future plans for expansion and application. As of October 31, 2021, the MMHB contains a continuously growing set of data from 578 patients and 104 healthy controls (46.37% female; median age, 38.31 years). The five most common mental health diagnoses in the MMHB are recurrent depressive disorder (38.78%; ICD-10: F33), alcohol-related disorders (19.88%; ICD-10: F10), schizophrenia (19.69%; ICD-10: F20), depressive episode (15.94%; ICD-10: F32), and personality disorders (13.78%; ICD-10: F60). Compared with the average patient treated at the recruiting hospitals, MMHB participants have significantly more mental health-related contacts, less severe symptoms, and a higher level of functioning. The distribution of diagnoses is also markedly different in MMHB participants compared with individuals who did not participate in the biobank. After establishing the necessary infrastructure and initiating recruitment, the major tasks for the next phase of the MMHB project are to improve the pace of participant enrollment, diversify the sociodemographic and diagnostic characteristics of the sample, and improve the utilization of real-world data generated in routine clinical practice. Translational research on complex, multifactorial mental health disorders, such as bipolar 78 disorder, major depressive disorder, schizophrenia, and substance use disorders requires 79 databases with large-scale, harmonized, and integrated real-world and research data. 80 The Munich Mental Health Biobank (MMHB) is a mental health-specific biobank that was 81 established in 2019 to collect, store, connect, and supply such high-quality phenotypic data 82 and biospecimens from patients and study participants, including healthy controls, recruited 83 at the Department of Psychiatry and Psychotherapy and the Institute of Psychiatric 84 Phenomics and Genomics, University Hospital of the Ludwig-Maximilians-University (LMU), 85 Munich, Germany. Participants are asked to complete a questionnaire that assesses 86 sociodemographic and cross-diagnostic clinical information, provide blood samples, and grant 87 access to their existing medical records. The generated data and biosamples are available to 88 both academic and industry researchers. In the current manuscript, we outline the workflow 89 and infrastructure of the MMHB, describe the clinical characteristics and representativeness 90 of the sample collected so far, and reveal future plans for expansion and application. 91 As of October 31, 2021, the MMHB contains a continuously growing set of data from 578 92 patients and 104 healthy controls (46.37% female; median age, 38.31 years). The five most 93 common mental health diagnoses in the MMHB are recurrent depressive disorder (38.78%; 94 ICD-10: F33), alcohol-related disorders (19.88%; ICD-10: F10), schizophrenia (19.69%; ICD-10: 95 F20), depressive episode (15.94%; ICD-10: F32), and personality disorders (13.78%; ICD-10: 96 F60). Compared with the average patient treated at the recruiting hospitals, MMHB 97 participants have significantly more mental health-related contacts, less severe symptoms, 98 and a higher level of functioning. The distribution of diagnoses is also markedly different in 99 MMHB participants compared with individuals who did not participate in the biobank. 100 After establishing the necessary infrastructure and initiating recruitment, the major tasks for 101 the next phase of the MMHB project are to improve the pace of participant enrollment, 102 diversify the sociodemographic and diagnostic characteristics of the sample, and improve the 103 utilization of real-world data generated in routine clinical practice. 104 105 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The MMHB phenotyping battery consists of three components: 1) a basic phenotyping 167 module, which builds on previous national multi-centric phenotyping efforts, such as the 168 PsyCourse Study and the PD-CAN study; 2) a module consisting of seven standardized self-169 rating measurements with cross-disorder utility; and 3) a variable module that highlights a 170 specific topic of research in more detail and changes every two years (Table 1 ) (9) . In 2020 171 and 2021, the variable module focused on metabolic risk, eating behavior, and stress related 172 to the COVID-19 pandemic. To reduce the biobanking-associated clinician workload, self-173 rather than observer-rating tools are used to obtain patient characteristics and symptom 174 scores. The MMHB phenotyping battery is complemented by data collected in association 175 with specific scientific projects or clinical trials. 176 177 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 7, 2022. ; https://doi.org/10.1101/2022.05.05.22274583 doi: medRxiv preprint Table S2 ). Participants may also be asked to provide saliva, hair, and 184 stool samples. 185 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Martinsried, Germany) and are stored at -80°C in an automated sample storage and 202 management system (BIOS M System, Hamilton Storage GmbH, Bonaduz, Switzerland) ( Figure 203 1). 204 205 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Clinical data and biological materials are stored in pseudonymized form in the information 207 management system CentraXX (Kairos GmbH, Bochum, Germany). Biological materials are 208 stored at -80°C, except for peripheral blood mononuclear cells, which are stored in liquid 209 nitrogen (Supplementary Table S2 ). Researchers can request data access by completing a 210 request form. If the Data Access Committee approves the request, a material and/or data 211 transfer agreement is signed, and the data and biological materials can be provided. 212 Abbreviations: CSF, cerebrospinal fluid; EHR, electronic health record; PBMCs, peripheral 213 blood mononuclear cells 214 215 2.6. Data availability 217 The collected phenotypes and biomaterials are available to both academic and industry 218 researchers upon request. The process for requesting data and biomaterials is as follows: 1) 219 Requestors send an email with a description of the planned scientific project, the type and 220 quantity of the requested data, and their data protection policies to the MMHB 221 (psy_mmhb@med.uni-muenchen.de) to inquire about data availability, and in the same 222 email, they may also propose collaborations with local researchers; 2) the Data Access 223 Committee evaluates the feasibility of the project and provides a cost estimate for sample 224 extraction, processing, and shipment; 3) at this point, requestors provide documentation 225 confirming ethical approval of the proposed project; 4) the MMHB provides a quote, data-226 and material transfer agreements (DTA and MTA, respectively); and 5) once the DTA and/or 227 MTA is signed by both parties, the biological materials and double-pseudonymized 228 phenotypic and omics data are sent to the requestor. Depending on the legal process, 229 approximately four to six months should be allowed from submission of the project proposal 230 to delivery of the data and/or biomaterials. and IPPG during the same period who were eligible for inclusion in the MMHB but were not 258 included). The two samples had similar age and sex distributions (Table 2) . Clinicians at the 259 DPP and IPPG routinely assess the seven-day functioning and disease severity of inpatients 260 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 7, 2022. ; https://doi.org/10.1101/2022.05.05.22274583 doi: medRxiv preprint Abbreviation: MMHB, Munich Mental Health Biobank 320 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 7, 2022. ; https://doi.org/10.1101/2022.05.05.22274583 doi: medRxiv preprint The MMHB is a mental health-specific biobank that aims to integrate multimodal research 322 and real-world phenotypic information with biosamples of patients with mental health 323 disorders and study participants, including healthy controls, to facilitate translatable mental 324 health research and, ultimately, improve patient care. Here, we outlined the information 325 technology and laboratory infrastructure and the administrative processes of the MMHB, 326 described the clinical and sociodemographic characteristics of the 578 patients and 104 327 healthy controls included in the MMHB so far and compared this sample with the overall 328 target population treated at the recruitment facilities. This initial evaluation allows us to 329 discuss the representativeness and scope of the MMHB sample, identify limitations of our 330 current recruitment strategy, and derive action points that could further improve the quality 331 of the MMHB data. 332 Representativeness 333 There is increasing evidence that individuals with certain non-random characteristics, such as 334 lower socioeconomic and education status, poorer health, non-European ancestry, and 335 increased cumulative genetic burden for schizophrenia, neuroticism, and attention-deficit 336 hyperactivity disorder, are less likely to participate in clinical studies and more likely to drop 337 out during the follow-up period (9, (23) (24) (25) . These data are concerning because non-338 participation and attrition not only are associated with a loss of statistical power, but, if non-339 random, can also influence sample representativeness and thereby bias the generalizability 340 and real-life utility of research findings, health policy decision-making, and ultimately, the 341 equity of health care provision (26). Compared with patients treated at the DPP and IPPG 342 since April 11, 2019 who were not included in the MMHB (Clinical Sample), we found that 343 certain mental health diagnoses, such as schizophrenia, schizoaffective disorder, alcohol-344 related disorders, and personality disorders, are overrepresented in the MMHB sample, 345 whereas adjustment disorders, for example, are relatively underrepresented, most likely 346 because recruitment so far has been propagated by study teams interested in answering 347 specific research questions. Interestingly, we found evidence that the frequency and length 348 of contact with the health care system differed between the target population (i.e., those not 349 included in the biobank) and the MMHB sample: MMHB participants were not only more 350 frequently hospitalized (median number of hospitalizations in MMHB Sample vs Clinical 351 Sample, 2 vs 1), but they also spent more days in hospital (median, 71 vs 37 days) and had 352 more outpatient appointments (6 vs 1) during the 30-month observational period. The 353 proportion of participants recruited in an inpatient setting was also higher in the MMHB 354 Sample than in the Clinical Sample (67.47% vs 22.93%). These differences could be explained 355 by potential systematic sampling biases in that study personnel and clinicians are more likely 356 to ask "known" patients to consent to being included in the MMHB and/or that patients with 357 repeated contacts with the same institution are more likely to trust that institution and 358 participate in its research efforts. Also, longer hospitalizations and more frequent visits in 359 general represent more opportunities to recruit participants. These observations emphasize 360 the importance of interpersonal factors (such as trust, rapport, and compliance) and the type 361 and frequency of contact with the health care system in study participation. These factors are 362 potential sources of recruitment bias that should be taken into consideration when analyzing 363 the MMHB Sample. Interestingly, despite the more frequent health care utilization, the 364 MMHB Sample had less severe symptoms and higher levels of functioning (measured with 365 CGI and GAF, respectively) at inclusion in the biobank than the Clinical Sample in general. 366 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Outlook 385 A key strength of the MMHB is its close integration into the clinical and scientific 386 infrastructure of a large mental health care center, which not only ensures the necessary 387 domain knowledge for collecting high-quality mental health-specific phenotypes, but also 388 provides direct access to the more than 3000 individual patients treated annually at the DPP 389 and IPPG and thus a strong growth potential ( Figure 3) . Moreover, this target population has 390 good sociodemographic representativeness because Germany has universal health insurance, 391 ensuring that treatment is offered to all individuals in need. A further asset of the MMHB is 392 the wide age range of eligible participants and the diversity of diagnoses, which enables the 393 study of all stages of the disease trajectory across the whole lifespan and diagnostic spectrum. 394 Limitations of the MMHB include the observed differences between the MMHB and Clinical 395 samples, the current sparsity of available real-world data, and the moderate recruitment pace 396 (only 5.56% of the 10,494 patients who were treated at the DPP and IPPG during the 30-397 month observational period and were thus eligible for inclusion were recruited into the 398 MMHB, Figure 3) . 399 To address these limitations, in the next phase of our biobanking effort, we will move from 400 active, interest-driven biobank recruitment towards a more passive, automatized 401 participatory system. To achieve this, we will first introduce the Broad Consent of the German 402 Medical Informatics Initiative, for which we have developed an additional Psychiatry Module 403 tailored to the needs of mental health research (30). This modified Broad Consent, which will 404 be valid for 5 years, will enable the scientific use of prospectively collected routine clinical and 405 insurance data, and, via the Psychiatry Module, additionally collected mental health-specific 406 phenotypes, magnetic resonance imaging, electroencephalogram data, and biosamples. 407 Next, we will introduce the Clinical Phenotyping Platform (CliPP), a software solution that 408 enables the collection of structured and standardized (Fast Healthcare Interoperability 409 Resource (FHIR) format) routine mental health data directly from patients and health care 410 providers. Owing to the Broad Consent and the CliPP, the consent process and the phenotypic 411 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 7, 2022. ; https://doi.org/10.1101/2022.05.05.22274583 doi: medRxiv preprint assessments will be incorporated into routine admission procedures. Their introduction will 412 broaden the available data modalities, reduce the time spent on patient recruitment, and 413 decrease the risk of sampling bias due to physician and/or patient preferences. Furthermore, 414 we will continuously monitor the representativeness of the MMHB Sample, analyze the 415 factors that influence biobank participation, and, if necessary, revise study design and 416 recruitment strategies. Through these measures, we will facilitate recruitment of participants 417 into the MMHB, improve clinician and patient commitment and the representativeness of our 418 sample, and ultimately, increase the scientific and clinical value of the MMHB Sample. Large 419 future transdiagnostic cohorts from the MMHB will leverage forward and reverse 420 translational research in an informative framework spanning preclinical models via disorder 421 focused clinical trials to real-world applications in a transdiagnostic spectrum of mental health 422 disorders including their developmental dynamics and co-morbidities. 423 424 425 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 7, 2022. ; https://doi.org/10.1101/2022.05.05.22274583 doi: medRxiv preprint Changes in the global burden of depression 427 from 1990 to 2017: Findings from the Global Burden of Disease study Case-finding for 430 common mental disorders of anxiety and depression in primary care: an external 431 validation of routinely collected data Large Study on Mental Health Genetics Launched by Estonian Biobank 433 Mental health phenotyping in UK Biobank Medical Informatics Initiative: Unlocking Data for 439 Research and Health Care Biobank 441 of Psychiatric Diseases Mannheim -BioPsy German Biobank Node as Coordinating Institution of the German Biobank Alliance: 444 Engaging with Stakeholders via Survey Research. Biopreservation Biobanking Biobanks for future medicine A 449 longitudinal approach to biological psychiatric research: The PsyCourse study The AUDIT alcohol consumption 453 questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory 454 Care Quality Improvement Project (ACQUIP) The brief resilience 460 scale: assessing the ability to bounce back A Short Scale for Measuring Loneliness 462 in Large Surveys: Results From Two Population-Based Studies Performance 465 of an abbreviated version of the Lubben Social Network Scale among three European 466 community-dwelling older adult populations The WHO-5 Well-Being Index: a 469 systematic review of the literature The PHQ-9: validity of a brief depression severity 471 measure Life between clocks: daily temporal patterns 473 of human chronotypes Prevalence of obesity, metabolic syndrome, 475 diabetes and risk of cardiovascular disease in a psychiatric inpatient sample: results of 476 the Metabolism in Psychiatry (MiP) Study. Eur Arch Psychiatry Clin Neurosci Psychometric analysis of the Three-Factor Eating Questionnaire-R21: results from a large 480 diverse sample of obese and non-obese participants Pandemic Mental Health Questionnaire (CoPaQ): psychometric evaluation and 484 compliance with countermeasures in psychiatric inpatients and non-clinical individuals. 485 BMC Psychiatry ECDEU assessment manual for psychopharmacology. US Department of Health A brief mental health outcome scale-489 reliability and validity of the Global Assessment of Functioning (GAF) Genetic 492 analyses identify widespread sex-differential participation bias Exploring the 495 association of genetic factors with participation in the Avon Longitudinal Study of 496 Parents and Children Genetic 498 predictors of participation in optional components of UK Biobank Larsson H. The importance of selection bias in prospective birth cohort studies Multimodal Machine Learning Workflows for Prediction of Psychosis in Patients With 504 Clinical High-Risk Syndromes and Recent-Onset Depression Validation 507 of an Electronic Health Record-Based Suicide Risk Prediction Modeling Approach Across 508 Multiple Health Care Systems Cross-510 trial prediction of treatment outcome in depression: a machine learning approach No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity